Ardelyx to Participate at the Jefferies Global Healthcare Conference 2025

Company Overview - Ardelyx, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative, first-in-class medicines to address significant unmet medical needs [3] - The company has two commercial products approved in the United States: IBSRELA (tenapanor) and XPHOZAH (tenapanor) [3] - Ardelyx has international agreements for the development and commercialization of tenapanor, including partnerships with Kyowa Kirin in Japan and Fosun Pharma in China [3] Upcoming Events - Mike Raab, President and CEO of Ardelyx, will participate in a fireside chat at the Jefferies Global Healthcare Conference 2025 on June 4, 2025, at 8:10 am ET in New York [1] - A live webcast of the panel presentation will be accessible on the Ardelyx website, with a replay available for 30 days post-event [2]